Although rare, there are cases within reported series of men with Gleason score (GS)r6 on radical prostatectomies that show pelvic lymph node (LN) metastases. However, there are no studies on whether pelvic LN metastases occur in tumors with GSr6 using the International Society of Urological Pathology (ISUP) updated GS system. We performed a search of the radical prostatectomy databases at 4 large academic centers for cases of GSr6. Only prostatectomies submitted and embedded in entirety with pelvic LN dissections were included. A combined total of 14,123 cases were identified, of which 22 cases had a positive LN. Histopathologic review of 19 cases (3 cases unavailable for review) showed higher grade than originally reported by the pathologists in all cases. Of the 17 pre-ISUP reviewed cases, 2 were upgraded to 4+3 = 7 with both cribriform and poorly formed glands. One case was upgraded to 4+3 = 7 with tertiary pattern 5 displaying cribriform glands, poorly formed glands, and cords of single cells. Eleven cases were upgraded to 3+4 = 7 with glomeruloid structures and small to large cribriform glands (1 of these also had features of ductal adenocarcinoma). Two cases had tertiary pattern 4 with small cribriform glands. One case had a prominent colloid component that would currently be graded as 4+5 = 9 because of large cribriform glands and solid sheets of cells within the mucin. Of the 2 post-ISUP cases, 1 demonstrated tertiary pattern 4, and the other showed GS 3+4 = 7 with irregular cribriform glands. Undergrading is the primary reason for LN positivity with GSr6, which has decreased significantly since the adoption of the ISUP grading system in 2005. Of over 14,000 totally embedded radical prostatectomies from multiple institutions, there was not a single case of a GSr6 tumor with LN metastases. In contrast to prevailing assumptions, GSr6 tumors do not appear to metastasize to LNs. Rather, Gleason pattern 4 or 5, as better defined by the current ISUP updated grading system, is required for metastatic disease.
M en with Gleason score (GS)r6 on biopsy are considered to have a risk, albeit very low, of lymph node (LN) metastases on radical prostatectomy (RP). The updated Partin Tables predict a percentage probability of LN metastases on RP of r1% in men with biopsy GSr6 if the prostate-specific antigen (PSA) is also r10 ng/mL. The predicted rate increases up to 5% if the PSA is >10 ng/mL and the clinical stage is T2b or T2c. 20 These cases could suffer from sampling artifact wherein highergrade cancer in the RP accounts for the source of metastatic disease. However, large series of RP from both single and multi-institutional data sets confirm the low rate of LN metastases in men with GSr6 on RP. 2, 6, 7, 26, 33, 34 All of these series include cases that were graded before the publication of the 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading. 9 The consensus paper outlined several patterns of Gleason 4 that in the past were considered as Gleason pattern 3 if one strictly used the original 1967 to 1971 Gleason grading system. In the current study, we performed a multi-institutional review of RP specimens with reported GSr6 and LN metastases. We hypothesized that these cases would be undergraded according to the modern post-ISUP grading scheme and that true Gleason pattern 3+3 = 6 does not have the potential to metastasize to LNs.
MATERIALS AND METHODS
A total of 14,123 RPs from 1975 to 2010 reported as GSr6 were identified from the combined RP databases of 4 large academic centers. Participating institutions were Johns Hopkins Hospital (JHH), Henry Ford Hospital, University of California San Francisco, and Baylor College of Medicine. Only RPs that were serially sectioned and entirely submitted were included in this study.
Cases were additionally split into 2 groups, with December 2004 as the breakpoint, reflecting when information of the updated ISUP Gleason grading scheme was available for the authors of the current study.
The extent of pelvic LN dissection varied between surgeons. At all the institutions, given that the vast majority of the patients in the current study were at low risk preoperatively, most urologists performed a standard node dissection consisting of the obturator and external iliac LNs, with a minority performing extended dissections removing the internal iliac nodes as well. For all participating institutions, the mean number of LNs removed including both the left and right sides was 8.7.
Of the 10,935 men identified in the RP database at JHH, 25 cases were coded by urologists in the database as GSr6 with a positive LN. Three cases were excluded because of an error in database entry or coding: pathologic reports confirmed either a higher grade or lack of positive LN. Another 2 cases were excluded because of the presence of a tertiary pattern 4 described in the initial pathology report but not accounted for in the database. Of the remaining 20 cases, 18 had blocks and/or slides available for review. Of the 3188 men identified in the RP databases at the remaining 3 academic centers (Henry Ford Hospital, University of California San Francisco, and Baylor College of Medicine) combined, 6 cases were coded in the database as GSr6 with a positive LN. Similar to the JHH database, 4 cases were excluded because of an error in database entry or coding: pathology reports confirmed higher grade in 2 cases or a lack of positive LN in another 2 cases. Of the remaining 2 cases, 1 was available for review, yielding a total of 19 cases for review from all institutions.
Significance testing was performed for continuous variables using a t test for the comparison of means. For dichotomous variables we performed the Pearson w 2 test. A P value <0.05 was considered statistically significant. All statistical analyses were performed using STATA release 12 (StataCorp LP, College Station, TX).
RESULTS
Considering the RP database at JHH separately, 10,935 men were identified with GSr6 on RP: 7332 pre-ISUP and 3603 post-ISUP. The pre-ISUP group appeared to have worse disease than the post-ISUP group with a higher mean presurgery PSA level (6.3 vs. 5.2, P < 0.0001). Similarly, in the pre-ISUP group, there were 19 cases with positive LNs compared with only 1 case in the post-ISUP group (0.26% vs. 0.03%, P = 0.008). Eighteen of 19 pre-ISUP cases with LN metastases had nonfocal extraprostatic extension, with 4 invading the seminal vesicles. The solitary post-ISUP case with an LN metastasis had focal extraprostatic extension.
Of the combined total of 14,123 cases from all 4 academic centers, including JHH, 22 cases were identified with GSr6 and a positive LN. Histopathologic re-review showed higher grade than originally reported by the pathologists in all 19 reviewed cases (3 unavailable for slide review) ( Table 1 ). Of the 17 pre-ISUP cases, 2 were upgraded to 4+3 = 7, displaying both cribriform and poorly formed glands. One case was upgraded to 4+3 = 7 with tertiary pattern 5 displaying cribriform glands, poorly formed glands, and cords of single cells ( Fig. 1 ). Eleven cases were upgraded to 3+4 = 7 showing several patterns considered Gleason 4 , including glomeruloid structures, small to large cribriform glands, and ductal adenocarcinoma features (Figs. 2A-C). Two cases had tertiary pattern 4 with small cribriform glands ( Fig. 2D ). One case had a prominent colloid carcinoma component that had not been factored into the grade in the original pathologic report. This case would be currently graded as 4+5 = 9 with large irregular cribriform glands and solid sheets of cells within pools of mucin ( Fig. 2E ). Of the 2 post-ISUP cases, 1 demonstrated a cribriform gland of tertiary pattern 4 on deeper sections as the original slides were not available. The second post-ISUP case was reported as GS 3+4 = 7 on biopsy. Although the RP GS was initially reported as 3+3 = 6, rereview showed GS 3+4 = 7 with irregular cribriform glands ( Fig. 2F ).
DISCUSSION
Reported large series of RP from both single and multi-institutional data sets report, albeit at a low rate, that GSr6 cancer has the ability to metastasize to pelvic LNs. von Bodman et al 33 men identified with GSr6 on RP, LN metastases were reported in 17 (0.2%). 1 Other large outcome series have shown higher LN metastasis rate of up to 3% in men with reported GSr6 on RP. 6, 7, 26, 34 To determine the true rate of GSr6 with positive LN at RP, we retrospectively identified and histologically reviewed these cases using the updated Gleason grading schema. Prior to histological review of the cases in the current study, a hypothesis to explain the higher incidence of GSr6 with LN metastases pre vs. post 2005 might have been that 1975-2005 encompassed cases in the pre-PSA era that were larger with a potential increased risk of LN metastasis. This explanation would have been consistent with the higher preoperative mean PSA in the pre-2005 cases when compared with the post-2005 cohort.
However, histologic review confirmed that undergrading primarily accounted for the larger number of cases with LN-positive GSr6 in the pre-ISUP era. Combining all 4 academic centers, 14 pre-ISUP cases were upgraded to GS 7 (3+4 in 11 cases, 4+3 in 2 cases, and 4+3 with tertiary 5 in 1 case). Cribriform glands were present in all 14 cases and represented the dominant source of upgrading on review of the slides. A major point of divergence of the updated from the original Gleason system is grading of cribriform glands. Within Gleason's 10 original illustrations of his cribriform pattern 3, he depicted large, cribriform glands. At the time of the 2005 ISUP grading consensus meeting, expert uropathologists had been uniformly diagnosing these lesions as cribriform pattern 4. The consensus conference proposed extremely stringent criteria for cribriform Gleason pattern 3. 9 However, when various images were shown to the participants of the consensus meeting, almost none of them met the criteria for cribriform pattern 3 on the basis of subtle features, such as slight irregularities of the outer border of the cribriform glands. It was the consensus that the vast majority of cribriform patterns be diagnosed as Gleason pattern 4 with only rare cribriform lesions satisfying diagnostic criteria for cribriform pattern 3. Subsequent to the 2005 meeting, a study reviewed 3590 consecutive prostate cancers from which 30 needle biopsy cases were selected that possibly represented cribriform Gleason pattern 3 cancer. 18 Even in a highly selected set of images thought to be the best candidates for cribriform pattern 3, most experts interpreted the cribriform patterns as pattern 4. There was poor reproducibility among experts with respect to cribriform pattern 3 versus pattern 4 because of: (1) disagreement as to what were the key diagnostic features in a given case (ie, irregular distribution of lumina and variable slit-like lumina, favoring pattern 4 vs. small glands and regular contour, favoring pattern 3; and (2) disagreement as to assessment of given criteria: regular versus irregular distribution of lumina and regular versus irregular contour. In a subsequent study specifically addressing the prognosis of cribriform prostate cancer glands, both small and large cribriform glands were equally linked to progression after RP. 16 These findings fit conceptually, as one would expect the change in grade from pattern 3 to pattern 4 to be reflected in a distinct architectural paradigm shift in which cribriform as opposed to individual glands are formed, rather than merely a subjective continuum of differences in size, shape, and contour of cribriform glands. The only reason why cribriform pattern 3 even exists is because of the original Gleason schematic diagram. Gleason never specifically published the prognostic difference between what he called cribriform Gleason pattern 3 compared with Gleason pattern 4. Many of Gleason's cribriform Gleason pattern 3 cancers may not even have been infiltrating carcinomas because of the lack of availability of immunohistochemical analysis for basal cell markers. Today we might have diagnosed them either as cribriform highgrade prostatic intraepithelial neoplasia or intraductal carcinoma of the prostate (concepts not present in Gleason's era). 3, 25 On the basis of all the above data, all cribriform cancers should be interpreted as Gleason pattern 4 and not pattern 3.
In the current series, 3 of our initially undergraded cancers also contained glomeruloid glands that we now regard as Gleason pattern 4. Glomeruloid structures are characterized by dilated glands containing an intraluminal cribriform structure with a single point of attachment. There was no consensus in the 2005 ISUP conference on grading glomeruloid glands. A study from our institution subsequent to the consensus conference indicated that glomerulations were overwhelmingly associated with concurrent Gleason pattern 4 or higher grade carcinoma. 19 One can also see a transition between small glomerulations, large glomeruloid structures, and cribriform pattern 4 cancer. These data suggest that glomerulations represent an early stage of cribriform pattern 4 cancer and are best graded as Gleason pattern 4.
Other minor patterns responsible for upgrading in our series included 3 cases with poorly formed glands and 1 with ductal adenocarcinoma features. These patterns were also added to the Gleason grading schema as Gleason pattern 4 only after the ISUP consensus panel in 2005. 9 The presence of tertiary pattern 4 in the RP represented a source of undergrading in several of our cases. In RP specimens, tertiary Gleason patterns are associated with higher pathologic stage and biochemical recurrence as compared with the same GS cancers without tertiary patterns. 12, 13, 22, 24, 27, 28, 30, 32, 35 GS 3+3 = 6 with tertiary pattern 4 has a prognosis between that for GS 3+3 = 6 without tertiary pattern 4 and GS 3+4 = 7. A problem with tertiary-grade patterns in RP is that they are not incorporated into the GS but merely noted separately in the pathology report. When institutions report GS in their databases and in subsequent articles relating to their databases, tertiary patterns are typically not included, which occurred in 2 cases within the current series. Another 3 cases had tertiary-grade patterns that were identified on review that were not noted in the original pathology report; tertiary-grade patterns in RP were first emphasized only in 2000. 22, 24 One case in our series was upgraded to Gleason 4+5 = 9. On review, there was a large colloid carcinomadominant nodule that had irregular cribriform structures and sheets of cells floating in mucin. Gleason pattern 3+3 = 6 was seen in a separate nodule. The original pathology report had assigned a grade only to the noncolloid adenocarcinoma. The ISUP consensus panel was split on whether to grade all colloid carcinomas as 4+4 = 8 or ignore the extracellular mucin and grade the tumor on the underlying architecture. Either method used would still upgrade the tumor in our case.
In addition to upgrading because of utilization of the updated Gleason grading system, 7 cases initially identified as GSr6 with LN metastasis in our databases represented an error in database entry. One study analyzing error in research oncology databases at a single institution detected error rates of up to 13.5% per database. 11 Errors were commonly seen with both incorrect and missing information.
One potential criticism of our study is that we did not review the cohort of GSr6 on RP without LN metastases. Presumably, some of those cases would also be upgraded on review. Although it may have reduced the denominator of the total number of cases with GSr6, the numerator of cases with GSr6 and LN metastasis would have remained unchanged. Our conclusion would be the same in that reports of LN metastases of GSr6 at RP are most likely due to pathologic undergrading. Another limitation of the current study is that most patients did not undergo extended LN dissection and hence metastases may have beenmissed. However, the more limited node dissection is currently standard of care in the United States for low-risk patients.
This study was particularly difficult to perform since many institutions do not submit and embed the prostate in its entirety. Otherwise, one could not be sure that a small focus of Gleason pattern 4 was left un-sampled. Even for the institutions in the current series, some potential cases were limited by an only recently adopted policy of total submission of the prostate in RP specimens. In addition, many surgeons do not perform LN dissections at the time of surgery with a GSr6 on biopsy unless the patient appears to be clinically high stage and/or has a high PSA. This restricted the number of participating institutions to 4, despite an initial attempt to include additional centers with large RP databases. However, of over 14,000 totally embedded RPs from multiple institutions with concurrent LN dissections, there was not a single case of a GSr6 tumor with LN metastasis. In contrast to prevailing assumptions, GSr6 tumors do not appear to metastasize to LNs. Rather, Gleason pattern 4 or 5, as better defined by the current ISUP updated grading system, is required for metastatic disease.
The current study also indirectly supports the greater accuracy of the updated Gleason system. The majority of studies have found that the updated needle biopsy grade correlates better with RP grade than does the original Gleason grade system. 14, 23, 31 Several studies have also demonstrated better correlation between the updated RP grade and outcome, compared with the original Gleason system grade. 4, 5, 29, 31 A consequence of the updated Gleason system is overall higher Gleason Scores when compared with the original Gleason system, reflecting the fact that some of the histologic features of Gleason pattern 3 in the original Gleason system are now classified as Gleason pattern 4 in the updated Gleason system. 5, 8, 14, 17, 23, 29 In the updated Gleason system, GSr6 is histologically more uniform with a more predictable excellent prognosis. In a previous study from one of the authors evaluating biochemical recurrence in men with pathologically organ-confined GSr6 at RP, histologic review assigned a higher grade to 24 of 38 cases with recurrence. Excluding these regraded cases, biochemical and local recurrence in this population was extremely rare. 21 Even including patients with non-organ-confined disease, patients with GSr6 in the post-ISUP era have an excellent prognosis with a 4-year biochemical cure rate of 97.6% after RP (Hopkins unpublished data). In an associated study, postoperative follow-up of over 2500 patients with GSr6 at RP (median, 5 y) showed no development of systemic disease or death due to prostatic adenocarcinoma. 15 On the basis of the current study, it can now be concluded that GSr6 using the updated system lacks the potential to metastasize to pelvic LNs.
